- Home
- AGL vs COGT Comparison
AGL vs COGT Comparison
Compare AGL & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGL
- COGT
- Stock Information
- Founded
- AGL 2016
- COGT 2014
- Country
- AGL United States
- COGT United States
- Employees
- AGL N/A
- COGT N/A
- Industry
- AGL Managed Health Care
- COGT Biotechnology: Pharmaceutical Preparations
- Sector
- AGL Health Care
- COGT Health Care
- Exchange
- AGL Nasdaq
- COGT Nasdaq
- Market Cap
- AGL 894.1M
- COGT 900.3M
- IPO Year
- AGL 2021
- COGT 2018
- Fundamental
- Price
- AGL $2.10
- COGT $7.90
- Analyst Decision
- AGL Hold
- COGT Buy
- Analyst Count
- AGL 18
- COGT 6
- Target Price
- AGL $4.38
- COGT $14.20
- AVG Volume (30 Days)
- AGL 3.6M
- COGT 1.7M
- Earning Date
- AGL 11-07-2024
- COGT 11-12-2024
- Dividend Yield
- AGL N/A
- COGT N/A
- EPS Growth
- AGL N/A
- COGT N/A
- EPS
- AGL N/A
- COGT N/A
- Revenue
- AGL $5,594,117,000.00
- COGT N/A
- Revenue This Year
- AGL $41.65
- COGT N/A
- Revenue Next Year
- AGL $10.30
- COGT N/A
- P/E Ratio
- AGL N/A
- COGT N/A
- Revenue Growth
- AGL 54.10
- COGT N/A
- 52 Week Low
- AGL $1.50
- COGT $4.28
- 52 Week High
- AGL $13.45
- COGT $12.61
- Technical
- Relative Strength Index (RSI)
- AGL 45.24
- COGT 32.81
- Support Level
- AGL $1.92
- COGT $7.94
- Resistance Level
- AGL $2.33
- COGT $8.56
- Average True Range (ATR)
- AGL 0.18
- COGT 0.60
- MACD
- AGL 0.02
- COGT -0.06
- Stochastic Oscillator
- AGL 25.38
- COGT 9.60
About AGL agilon health inc.
Agilon Health Inc is transforming healthcare by empowering primary care physicians for the health of the patients. The company enables physicians to create their own Medicare-centric globally capitated line of business. The company derives its revenue from Medical services.
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling.